Vital sets IPO range

Liver disease company Vital Therapies Inc. (San Diego, Calif.) amended its IPO on NASDAQ and now plans to sell 4.5 million shares at $13-$15. At the $14 midpoint, the company would raise $63 million and be valued at $295.6 million. BofA Merrill Lynch; Credit Suisse; William Blair; and Canaccord are underwriters. The company postponed its IPO in November, citing market conditions. Last month, Vital filed an S-1A that no longer contained a share price or proposed number of shares. Before the postponement, the company had planned to sell 4.4 million shares at $16-$18. ...